Get started
Author

K.B. Kim

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).
2011 · J. R. Infante, G. S. Falchook, et al. · Journal of Clinical Oncology · 121
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial
2014 · A.M. Menzies, M.T. Ashworth, et al. · Annals of Oncology · 91
The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population‐based matched cohort study in Korea
2019 · H.S. Kim, H.J. Kim, et al. · British Journal of Dermatology · 37
1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM)
2023 · M. Mckean, B. Chmielowski, et al. · Annals of Oncology · 25
PDF
1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma
2024 · M.O. Butler, R. Weight, et al. · Annals of Oncology · 3
PDF
1097P Long-term follow-up of advanced melanoma (unresectable/metastatic - aMel) patients (pts) treated with fianlimab (FIAN) + cemiplimab (CEMI): Results from blinded independent central review (BICR) efficacy assessment
2024 · M. Mckean, A.M. Weise, et al. · Annals of Oncology · 1
PDF
Gridded Population Projection of South Korea Using Ensemble Machine Learning (2025–2060)
2026 · Jaeheon Jung, Oh Seok Kim, et al. · Spatial Demography
Fianlimab + cemiplimab in patients with advanced melanoma: Subgroup analyses by blinded independent central review (BICR)
2025 · M. McKean, A. Weise, et al. · EJC Skin Cancer
Works count: 8
Citation count: 278
H-index: 4
I10-index: 4
Year
Topic
Type